In its Q1 2026 filing, IRIDEX disclosed approximately $6.4 million in non-current and $1.5 million in current deferred revenue related to exclusive distribution rights, highlighting growing commercial adoption under sales-based license agreements with delayed revenue recognition. The company’s proprietary MicroPulse® and Endpoint Management™ technologies provide clinically safer alternatives to conventional continuous-wave lasers for glaucoma and retinal disease treatment, supported by recurring consumables sales and direct distribution in key markets. While IRIDEX operates within a niche with supply chain and customer concentration challenges, recent reimbursement clarifications and expanded distribution offer growth levers. The balance sheet shows prudent liquidity management with a current ratio near 2 and low debt relative to cash reserves.